Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Gross Margin: 2021-2024

Historic Gross Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to 85.61%.

  • Kiniksa Pharmaceuticals International's Gross Margin rose 672.00% to 88.80% in Q3 2025 from the same period last year, while for Sep 2025 it was 87.52%, marking a year-over-year increase of 121.00%. This contributed to the annual value of 85.61% for FY2024, which is 203.00% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Gross Margin stood at 85.61% for FY2024, which was down 2.32% from 87.64% recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Gross Margin ranged from a high of 87.64% in FY2023 and a low of -128.95% during FY2022.
  • Moreover, its 3-year median value for Gross Margin was 85.61% (2024), whereas its average is 14.77%.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Gross Margin crashed by 20,534bps in 2022 and then skyrocketed by 21,659bps in 2023.
  • Yearly analysis of 4 years shows Kiniksa Pharmaceuticals International's Gross Margin stood at 76.39% in 2021, then slumped by 20,534bps to -128.95% in 2022, then spiked by 21,659bps to 87.64% in 2023, then tumbled by 203bps to 85.61% in 2024.